Kristin Abate, Chief Accounting Officer at Karyopharm Therapeutics Inc. (KPTI), sold 23 shares at $6.43 ($148) on 2025-09-15, disclosed to the SEC on 2025-09-16.
Open-market sale of $148 KPTI by Chief Accounting Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| KPTI | SELL | 2026-05-15 | $504 | — | Filing → |
| KPTI | SELL | 2026-03-03 | $5K | — | Filing → |
| KPTI | SELL | 2026-01-29 | $352 | — | Filing → |